TNDM250117P42500
- 6.40
- +0.60+10.34%
Tandem Diabetes Care Newsroom
Benzinga Market Summary: S&P Rises On PCE Data, Novo Nordisk Falls On Weight Loss Data, Diabetes Stocks Rise
Tandem Diabetes Care Shares Are Trading Higher Amid Strength in Diabetes-related Stocks Following Weight Loss Data From Novo Nordisk.
DexCom, Insulet, Tandem Benefit From Novo Nordisk CagriSema Data
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
The Market Lifts Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares 25% But It Can Do More
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $50
Express News | Tandem T:Slim X2 Insulin Pump Now Compatible With Dexcom G7 Cgm in Canada
Tandem T:slim X2 Insulin Pump Now Compatible With Dexcom G7 CGM in Canada
Express News | Tandem Diabetes Care Inc : Canaccord Genuity Raises Target Price to $63 From $56
TD Cowen Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Cuts Target Price to $40
Tandem Diabetes Care Poised for Growth: Expansion Into Type 2 Diabetes and Strategic Integration Drive Buy Rating
Tandem Diabetes Care (TNDM) Down 9.2% Since Last Earnings Report: Can It Rebound?
United States Diabetes Device Market Forecast Report and Company Analysis 2024-2032 Featuring BD, Roche, Medtronic, Insulet, Abbott, Dexcom, Tandem Diabetes Care, Ypsomed Novo Nordisk, Eli Lilly - ResearchAndMarkets.com
Morgan Stanley Bullish on Medtech in 2025, Upgrades 5 Stocks
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Tandem Diabetes Care Raised to Overweight From Equal-Weight by Morgan Stanley
Morgan Stanley Upgrades Tandem Diabetes Care(TNDM.US) to Buy Rating, Maintains Target Price $45
Leerink Partners Keeps Their Buy Rating on Tandem Diabetes Care (TNDM)
Express News | Tandem Diabetes Care Inc : Leerink Partners Cuts Target Price to $58 From $59
This Insider Has Just Sold Shares In Tandem Diabetes Care